4.8 Article

Ice-COLD-PCR enables rapid amplification and robust enrichment for low-abundance unknown DNA mutations

Journal

NUCLEIC ACIDS RESEARCH
Volume 39, Issue 1, Pages -

Publisher

OXFORD UNIV PRESS
DOI: 10.1093/nar/gkq899

Keywords

-

Funding

  1. German Ministry for Research and Education [FKZ 0313940, PTJ-Bio/0313735/Nn07-06, PTJ-Bio/0315271A]
  2. Deutsche Forschungsgemeinschaft [DFG Wi2648, DFG Schi 505/5-1]
  3. European Union [FlpFlex MEST-CT-2004-504990, LSHB-CT-2006-018933]
  4. European Community [MEST-2004-504990]
  5. NATIONAL CANCER INSTITUTE [R21CA138280, T32CA009078, R21CA111994, R33CA111994] Funding Source: NIH RePORTER

Ask authors/readers for more resources

Identifying low-abundance mutations within wild-type DNA is important in several fields of medicine, including cancer, prenatal diagnosis and infectious diseases. However, utilizing the clinical and diagnostic potential of rare mutations is limited by sensitivity of the molecular techniques employed, especially when the type and position of mutations are unknown. We have developed a novel platform that incorporates a synthetic reference sequence within a polymerase chain reaction (PCR) reaction, designed to enhance amplification of unknown mutant sequences during COLD-PCR (CO-amplification at Lower Denaturation temperature). This new platform enables an Improved and Complete Enrichment (ice-COLD-PCR) for all mutation types and eliminates shortcomings of previous formats of COLD-PCR. We evaluated ice-COLD-PCR enrichment in regions of TP53 in serially diluted mutant and wild-type DNA mixtures. Conventional-PCR, COLD-PCR and ice-COLD-PCR amplicons were run in parallel and sequenced to determine final mutation abundance for a range of mutations representing all possible single base changes. Amplification by ice-COLD-PCR enriched all mutation types and allowed identification of mutation abundances down to 1%, and 0.1% by Sanger sequencing or pyrosequencing, respectively, surpassing the capabilities of other forms of PCR. Ice-COLD-PCR will help elucidate the clinical significance of low-abundance mutations and our understanding of cancer origin, evolution, recurrence-risk and treatment diagnostics.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available